| pubmed-article:10517187 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0040300 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0102118 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0255672 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0475264 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:10517187 | lifeskim:mentions | umls-concept:C0205144 | lld:lifeskim |
| pubmed-article:10517187 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10517187 | pubmed:dateCreated | 1999-11-3 | lld:pubmed |
| pubmed-article:10517187 | pubmed:abstractText | The hypothesis of the present work was that the pannus tissue overlying the articular hard tissues has an aggressive phenotype and contains the newly discovered collagenase-3 and its endogenous inducers and activators. We therefore analyzed the eventual presence of collagenase-3 and its regulation at the pannus-cartilage junction. Collagenase-3 mRNA (in situ hybridization) and enzyme protein (ABC and immunofluorescence staining) were found in the pannocytes in the pannus-hard tissue junction. Inflammatory round cells associated with the critical interface contained TNF-alpha and IL-1beta. These cytokines induced collagenase-3 secretion in cultured rheumatoid synovial fibroblasts. Procollagenase-3 activators, stromelysin-1, 72 kDa type IV collagenase/gelatinase and membrane-type 1-MMP, were also found in the pannus-hard tissue junction. Active collagenase-3 was inhibited with alendronate (IC50 = 500-750 microM). Collagenase-3, due to its substrate profile and local synthesis in a milieu favoring its activation, might play a major role in the degradation of cartilage type II and bone type I collagens. Alendronate, at concentrations attainable in vivo, is able to inhibit collagenase-3. This might offer an option to control collagenase-3-mediated tissue destruction in rheumatoid arthritis. | lld:pubmed |
| pubmed-article:10517187 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10517187 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10517187 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10517187 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10517187 | pubmed:issn | 0945-053X | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:SantavirtaSS | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:SorsaTT | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:XuJ WJW | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:KonttinenY... | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:SalaFF | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:López-OtínCC | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:HanemaaijerRR | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:TeronenOO | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:CeponisAA | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:VallealaHH | lld:pubmed |
| pubmed-article:10517187 | pubmed:author | pubmed-author:SutinenMM | lld:pubmed |
| pubmed-article:10517187 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10517187 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:10517187 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10517187 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10517187 | pubmed:pagination | 401-12 | lld:pubmed |
| pubmed-article:10517187 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:meshHeading | pubmed-meshheading:10517187... | lld:pubmed |
| pubmed-article:10517187 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10517187 | pubmed:articleTitle | Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. | lld:pubmed |
| pubmed-article:10517187 | pubmed:affiliation | Department of Medicine, Helsinki University Central Hospital, Finland. yrjo.konttinen@helsinki.fi | lld:pubmed |
| pubmed-article:10517187 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10517187 | lld:pubmed |
